chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Patient with history of COVID vaccines who admitted to hospital with COVID detected PCR. Provider d/c note: "Patient is a 68YO female with past medical history of COPD, HTN, DM2 who presented to the hospital from AFC on 6/25/23 with worsening cough, shortness of breath, and wheezing for few days prior to admission. Patient required frequent use of her rescue inhaler which made her concerned. Patient reports multiple individuals at AFC were diagnosed with COVID-19. Symptoms upon presentation included productive cough of clear-yellow sputum and shortness of breath. She denied fever, chills, weakness, abdominal pain, N/V/D/C. Patient received DuoNebs and Solu-medrol prior to arrival in the ED by EMS. ED work-up was remarkable for hypoxia and tachycardia. Labs were notable for leukocytosis with elevated neutrophils, lymphocytes. RVP was positive for COVID-19. Patient was placed on BiPAP due to respiratory status and eventually weaned off prior to admission. Patient was admitted for presumed COPD exacerbation in the setting of COVID-19.    Patient's hospitalization was unremarkable, she was initially started on Azithromycin and Rocephin for presumed underlying superimposed bacterial pneumonia. Chest XR findings were unremarkable so Rocephin was discontinued prior to discharge. Patient completed a 3-day course of Azithromycin for COPD exacerbation. Patient was also weaned down on oxygen to 0.5-1L to maintain SpO2 88-94%. Patient was on telemetry for hx of paroxysmal Afib with normal rate. Given that patient uses 2L NC SpO2 at baseline, she did not require a walk test prior to discharge. However, patient was encouraged to decrease her home O2 to none at rest and 0.5-1L with exertion.  The patient's leukocyte count remained elevated, presumed reactive from her current infection and COPD exacerbation; however, it was recommended that patient repeat a CBC in 1 month, and if abnormal, follow-up with Hematology. Patient was discharged back to AFC (Home) in stable condition with recommendations to continue Prednisone for 2 additional days"
Pt experienced macular rash, greater than 15 on torso/chest, less than 50 on face.  No vesicles.
Pt experienced problems with seeing, walking into things, tripping over things, sits close to television, blurred vision, cataracts. Had a lensectomy on 6/27/00.
Adult Pfizer/BioNTech vaccine 0.3 ml (Grey top for ages 12 and up) was administered instead of pediatric Pfizer/BioNTech vaccine 0.2ml (Orange top for 5 to <12).  No adverse effect noted. Error discovered on 03/25/22 (11 days later) when staff were entering administration into State immunization system. Spoke with patient's mom after error discovered and she reported child had sore arm after injection for a day or so that had resolved and no other effects.  Mom reported child was doing fine. Child is 63.5 in tall and weighs 160lbs. Pediatric provider recommended patient not receive scheduled booster. Mom agreed.
The patient reported no current adverse event experienced or any effect requiring medical attention.  The patient was instructed to contact the pharmacy if any adverse events occur.
no adverse event; Vaqta and Gardasil 9 were administered to a patient on 6/2/21 prior to discovering temperature excursion; This spontaneous report was received from a medical assistant and refers to a 18-year-old patient of unknown gender. The patient's pertinent medical history, drug reactions, allergies and concomitant medications were not reported.  On 02-JUN-2021, the patient was vaccinated with an improperly stored doses of hepatitis a vaccine, inactivated (VAQTA) lot # T023914, expiration date 31-MAR-2022, at a dose of 0.5 milliliter, intramuscularly and hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) lot # T025370, expiration date 01-DEC-2022, at a dose of 0.5 ml, intramuscularly for prophylaxis (anatomical locations were not provided). The temperature excursion was below 2 Celsius degrees (1,1 Celsius degrees) for 14 hours. There were no previous excursions reported. The digital data logger was involved. No additional adverse event.
Severe headache, shortness of breath, severe increase in chest pain, positive POC troponin
mild flu like symptoms; Mild fever; sore throat; lymph nodes; ears feel clogged; This is a spontaneous report received from a contactable consumer, the patient. A 36-Year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, lot number: unknown)  via an unspecified route of administration in her left arm on 26Feb2021 at 09:00 (at the age of 36-years-old) as a single dose for COVID-19 immunisation. Medical history included psoriasis, bipolar and post-traumatic stress disorder (PTSD). Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. Concomitant medications included clonazepam (KLONOPIN), lamotrigine (LAMICTAL), quetiapine fumarate (SEROQUEL) and escitalopram oxalate (LEXAPRO) all for an unknown indication and from an unknown date. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: unknown) via an unspecified route of administration on an unspecified date as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within 4 weeks prior to the COVID-19 vaccine. On 26Feb2021 at 09;00, the patient experienced mild flu like symptoms every day at the same time each day, felt after the second dose, but was not nearly as symptomatic, mild fever, sore throat, swollen lymph nodes and ears feet clogged. The adverse events did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the reported events. The clinical outcomes of the events flu like symptoms, mild fever, sore throat, lymph nodes and ears feel clogged was unknown at the time of this report.   Information about lot/batch number cannot be obtained. No further information is expected
Patient had an episode within 2-3 minutes of the injection where her left chest wall became tight and the left arm became warm.  She then recalls wanting to sit down.  Her husband helped her to the chair.  Witnesses reported that her eyes rolled back in her head and she had myoclonic type jerking.  The patient felt like her thoughts were jumbled.  She was confused for several hours after the episode.  Has not had a history of seizures.  Has had history of fainting.
Swelling in right arm pit noticed on October 16 at 6AM. Swollen are was about 4" long, 2" wide, and about 1" high and located approximately in center of arm pit.   It was not painful and there was no redness nor any sign of insect bite.  I went hiking that day and felt well as normal. Upon examination by health care personnel on October 18, they found my lymph nodes in right arm pit to be swollen and hard.
Presents to clinic for palpitations, nausea the morning after the vaccines. Recommend EKG at urgent care and Holter monitoring with primary care physician.
Somewhat severe armpit lymph node pain and swelling (golf ball sized swelling). Only on armpit of the right arm. Swelling and pain persisted for 4 days following presentation.
Patient states that several hours after menomune shot experienced transient paralysis of limps, eyelids and mouth. Resulted in ER visit. Patient observed and released.
Approximately 2 inch red circle, warm to touch that lasted about 3 days. Patient reports spike in blood sugars (190-210) over normal blood sugar (100-130) for approximately 3 days but have since returned to normal. Patient reports having had similar reactions in past but this years was more pronounced and lasted longer.
confused, not walking well, fever, fatigue.  Went to ER by ambulance and was given IV fluids which helped improve pt's status and was discharge home in stable condition.  Was diagnoses with dehydration and fatigue.  All symptoms were resolved on 3-15-21
Information has been received from a physician concerning a female who was vaccinated with a dose of GARDASIL by intramuscular injection in to her arm (lot number not reported). Just as the needle was being pulled out of the patient's arm, the patient experienced seizure.  Unspecified medical attention was sought.  Upon internal review seizure was determined to be an other important medical event.  Additional information has been requested.
Supraclavicular pains and swelling X 1 day after dual administration of smallpox and Anthrax vaccines.
After about an hour, heart palpitations, shaky hands & feeling dizzy & sick. Stopped after about 2 hours. Then next morning, swollen fingers and hives on hands, took allergy pill and went away. Several days later, swelling of right eyelid and face (cheeks) and hives on various places on the body. Took Benadryl and after about 24 hours went away. Since then, on a daily basis, hives on hands, legs torso, etc.
Aches and pains throughout body, felt feverish but no fever, complained of chills on and off, nausea, dizzy Gave ibuprofen at 1:00 p.m. Gave zyrtex at 4:00 p.m.
Body aches, fever, headache and fatigue throughout the day on May 16. Fever at 103 degrees at 4pm Intense chest pain and shortness of breath 10:00pm May 16-2:30am May 17 - administered 500 mg Tylenol at 7pm and 1am Visited pediatrician on May 17. Vitals normal other than a fever. Intense chest pain  8:00pm-10:00pm May 17. Fever at 101.5 - administered 500 mg Tylenol at 8:45pm Work up morning of May 18 at 5:30am with intense chest pain - administered 500mg Tylenol at 6:10am
Hospitalization for COVID pneumonia/hypoxemia 8/15-8/21/2021. Treated with dexamethasone 6 mg  IV daily; Remdesivir for 5 days; Expired 08/21/2021.
Flumist received on Saturday, 12/27/08.  On Tues. 12/30/08 began experiencing itching of nasal cavity, nasal infection, nasal bleeding, 101 degrees F temp.; aching neck & back.  Contacted PMD, who did rapid flu which was positive.  Called CDC and was told to report to local health dept.
3 days after receiving the FLUBLOK vaccine ended up in the Emergency Room with Myocarditis; not sure if this was symptoms of COVID or if he was truly having a reaction to the FLUBLOK; Initial information received on 27-Jan-2022 regarding an unsolicited valid serious case was received from a pharmacist via sales representative.  This case involves a 19 years old male patient who was not sure if this was symptoms of COVID or if he was truly having a reaction to the FLUBLOK and ended up in the emergency room with myocarditis 3 days after receiving the influenza quadrivalent recombinant vaccine [Flublok QIV] vaccine.  The patient's past medical history, medical treatment(s), vaccination(s), concomitant medication(s) and family history were not provided.   On an unknown date, the patient received influenza quadrivalent recombinant vaccine (strength, formulation, dosage, lot number not reported) via unknown route in unknown administration site for prophylactic vaccination. Information on batch number was requested.   Reportedly, patient's mom was not sure if this was symptoms of COVID (Suspected COVID-19; unknown latency) or if he was truly having a reaction to the influenza quadrivalent recombinant vaccine. On an unknown date, 3 days after receiving the influenza quadrivalent recombinant vaccine ended up in the emergency room with myocarditis (myocarditis). The event (myocarditis) was assessed as medically significant.  Action taken with QUADRIVALENT RECOMBINANT INFLUENZA VACCINE (FLUBLOK QIV) was not applicable.  It was not reported if the patient received a corrective treatment for the event (myocarditis, Suspected COVID-19).  At time of reporting, the outcome was Unknown for the event of myocarditis and unknown for Suspected COVID-19.; Sender's Comments: Company Comment dated 07-Feb-2022: This case involves a 19 years old male patient who ended up in the emergency room with myocarditis 3 days after receiving the influenza quadrivalent recombinant vaccine [Flublok QIV] vaccine. The time to onset was compatible for the event. Further information regarding medical history, concurrent condition during vaccination, previous vaccination, concomitant medication and tolerance, allergic history, laboratory investigations excluding alternative etiologies for the reported event are needed to fully assess this case. Based upon the reported information, the role of the suspect vaccine cannot be assessed.
The left armpit was incredibly tender and noticed that something felt like it was under my arm. A month later, the lump came back and migrated down my arm from the shoulder to the elbow. I also had pain in the left breast.
Baseline normal CBC, abnormal WBC diffs since administration. Development of inflammatory bowel disease; collagenous colitis. Progressed from mild to serious, on long term disability at this time. The 60 day follow up received on 10/1/03 states continued inflammatory bowel disease, gastritis, duodualitis, unable to work, pain, diarrhea, inconsistent lab values.  Follow up on 11/10/04 states: "I am a nurse who made a report last year. I recently discovered the source of my health problems is an IgG deficiency, which would have appeared around the same time as my varicella injection. I was not born with it. Please advise me of any other reports that indicate an immune system disorder. There are 292 cases listed in MMWR 01/24/03.  Thank you." Follow-up Information 28-SEP-2007: Suspect if Varicella injection x 2 administered to titer immune 47 y.o. woman as healthy control in research study. Pt stated asymptomatic of health problem, CBS and diff prevaccine normal. Pt began to experience symptoms of autoimmune collagenous collitis within 3 weks post injection. Patient developed multiple diseases of potential autoimmune etiology. Frozen specimens prevaccine frozen and found pt to have Hypogammaglobulinemia preinjection which is contraindication provoking CVID.
Information has been received from a physician concerning a 19 year old female who was vaccinated with the three dose series of GARDASIL (lot # 657868/0523U), 658556/1060U, 659439/1267U, respectively), was completed on 08-JAN-2008. In April of 2008, the patient experienced uveitis and was treated with prednisone. The symptoms continued to the time of the report, 22-AUG-2008. No other information was available. Additional information has been requested. Follow-up information was received via medical records. The patient was vaccinated with a first dose of GARDASIL on 15-JUN-2007 (lot # 657868/0523U), a second dose on 24-AUG-2007 (lot # 658556/1060U) and a third on 15-JUN-2008 (lot # 659439/1267U) respectively in the left arm. At the time of diagnosis with uveitis the patient was on KARIVA. The patient was also diagnosed with mononucleosis prior to uveitis. On 03-APR-2008 the patient had a lyme IgG/IgM Ab test performed and was negative. the patient also had a complete blood test performed and the results were normal. The patient recovered on an unspecified date but received 2 weeks of prednisone and intrancular steroid injection. On 14-JUL-2008 the patient had an evaluation at the eye center. The patient was started on KENALOG daily and was off prednisone with recurrent headache behind both eyes, photophobia, redness, no vision changes and chronic "flickering" right eye. The patient also had decreased optic disc edema. The patient was doing well and follow-up was in 2 months. Previous vaccinations included MENACTRA and DTAP on 15-JUN-2007. The reporting physician felt that uveitis was an other medical event. Additional informatio is not expected. Medical records are available upon request.
Within several minutes of receiving the flu shot (FLUAD), patient complained of difficulty breathing. No other symptoms. Patient's husband retrieved her oxygen unit and said she had been very active during the day, had COPD, and indicated the breathing problems had occurred before. Within 10-15 minutes patient had responded to her rescue inhaler and oxygen. 911 was called and patient was taken to hospital.
HERPES ZOSTER IN A PREVIOUSLY VACCINATED CHILD.  THE RASH WAS IN THE C5 DERMATOME AND RESOLVED WITHOUT COMPLICATION. CHILD HAS NO HISTORY OF VARICELLA ILLNESS.
Presented w/SOB. Admit for COVID PNA. HX of asthma, diabetes. Tx w/remdesivir, ABX, steroid, vitamins, O2. Discharged to home on home O2.
Erythromelagia, neuropathy, POtS; Erythromelagia, neuropathy, POtS; Erythromelagia, neuropathy, POtS; Inappropriate route of vaccination; This spontaneous case was reported by a consumer and describes the occurrence of NEUROPATHY PERIPHERAL (Erythromelagia, neuropathy, POtS), ERYTHROMELALGIA (Erythromelagia, neuropathy, POtS) and POSTURAL ORTHOSTATIC TACHYCARDIA SYNDROME (Erythromelagia, neuropathy, POtS) in a 46-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Concurrent medical conditions included Food intolerance (No food allergies but can tolerate very little foods.).   On 08-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 08-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Cutaneous) dosage was changed to 1 dosage form. On 08-Feb-2021, the patient experienced INCORRECT ROUTE OF PRODUCT ADMINISTRATION (Inappropriate route of vaccination). On 18-Feb-2021, the patient experienced NEUROPATHY PERIPHERAL (Erythromelagia, neuropathy, POtS) (seriousness criterion medically significant), ERYTHROMELALGIA (Erythromelagia, neuropathy, POtS) (seriousness criterion medically significant) and POSTURAL ORTHOSTATIC TACHYCARDIA SYNDROME (Erythromelagia, neuropathy, POtS) (seriousness criterion medically significant). On 08-Feb-2021, INCORRECT ROUTE OF PRODUCT ADMINISTRATION (Inappropriate route of vaccination) had resolved. At the time of the report, NEUROPATHY PERIPHERAL (Erythromelagia, neuropathy, POtS), ERYTHROMELALGIA (Erythromelagia, neuropathy, POtS) and POSTURAL ORTHOSTATIC TACHYCARDIA SYNDROME (Erythromelagia, neuropathy, POtS) had not resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Body temperature: fluctuations (abnormal) fluctuations in feet.   Concomitant medication were not provided  Treatment medication were not reported.  It was reported that, 2 weeks after vaccine patient started having hot feet and it was progress to bulging veins, tingling in face, hands and feet.  Company Comment: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.
I had a slight reaction like a flu for 24 hrs. I did have a breakthrough case of Covid a year later symptoms started around 9pm 01/06/2022. Tested positive on 01/07/2022.
This spontaneous report was received from a registered nurse concerning a 4 year old patient of unknown gender. On 05-SEP-2013, the patient was vaccinated with a dose of an improperly stored M-M-R II (lot number and expiry date were reported as H018950 and 18-OCT-2014 respectively, dose and route unspecified) which was exposed to 66 degrees Fahrenheit (F) for 41.5 hours. No concomitant therapy was reported. No adverse effects were reported. This is one of the two reports from the same source. Additional information has been requested.
01/04/23 presents to ED for "shortness of breath". PMHx of "Sjogren's disease"
Stuffy nose; Arm hurt; Tired; This spontaneous case was reported by a consumer and describes the occurrence of NASAL CONGESTION (Stuffy nose), PAIN IN EXTREMITY (Arm hurt) and FATIGUE (Tired) in an 83-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concurrent medical conditions included Knee pain and Back pain. Concomitant products included NAPROXEN SODIUM (ALEVE) for Knee pain and Back pain.    On 02-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 02-Feb-2021, the patient experienced NASAL CONGESTION (Stuffy nose), PAIN IN EXTREMITY (Arm hurt) and FATIGUE (Tired). At the time of the report, NASAL CONGESTION (Stuffy nose), PAIN IN EXTREMITY (Arm hurt) and FATIGUE (Tired) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Treatment medication was not reported.   Reporter did not allow further contact
This spontaneous report was received from the patient's grandmother referring to her grandson a male patient of unknown age. The patient's pertinent medical history, drug reaction/allergies or concomitant medication were not reported. In approximately 2010 (reported as "about six years ago"), the patient's mother received a dose of GARDASIL (route, dosage schedule, lot # and expiration date were not reported) while pregnant. The reporter also stated that since an unknown date (reported as "now") the patient was "acting out' (impulsive behavior). The outcome of the patient's impulsive behavior and was unknown at the reporting time. The reporter did not assess causality between the event and the use of GARDASIL. This is one of two reports received from the same reporter. The reporter considered the event to be a congenital anomaly. Additional information is not expected as the reported refused contact for follow up.
Information has been received from a lawyer regarding a case in litigation concerning a female patient of unknown age. No information was received regarding the patient's past medical history, concurrent conditions, or concomitant medication. In 01-MAR-2014, the patient was inoculated with ZOSTAVAX (lot number, dosage and route of administration not provided), at a pharmacy as recommended for routine adult health maintenance and for the prevention of shingles. The ZOSTAVAX did not prevent shingles as intended, and the patient subsequently contracted a persistent strain of herpes zoster. On or about 08-SEP-2014, the patient was treated by a physician for a persistent and severe vesicular rash, which was diagnosed as post-herpetic neuralgia, a chronic condition of pain and nerve damage secondary to herpes zoster infections. The patient was also diagnosed with thoracic neuropathy, secondary to shingles complications. The patient was prescribed gabapentin for management of her painful symptoms and chronic pain. As a direct and proximate result of the ZOSTAVAX vaccine, and/or despite receiving ZOSTAVAX for long-term prevention of shingles, the patient suffered painful injuries and damages, and required extensive medical care and treatment. As a further proximate result, the patient has suffered and will continue to suffer significant medical expenses, and pain and suffering, and other damages. The outcome is unknown. Upon internal review, thoracic neuropathy was determined to be medically significant. Additional information has been requested.
Shortness of breath while exercising outdoors happening on 6 separate occasions. Currently exercise 4-7days per week with no previous shortness of breath events. No previous Covid diagnosis   Additionally, heart palpitations while working out not experienced before